Replimune Group Inc [REPL] stock is trading at $14.93, up 35.11%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The REPL shares have gain 38.24% over the last week, with a monthly amount glided 24.83%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Replimune Group Inc [NASDAQ: REPL] stock has seen the most recent analyst activity on August 28, 2024, when ROTH MKM initiated its Buy rating and assigned the stock a price target of $17. On November 19, 2021, Piper Sandler initiated with a Overweight rating and assigned a price target of $52 on the stock. BTIG Research initiated its recommendation with a Buy and recommended $60 as its price target on November 17, 2020. Jefferies started tracking with a Buy rating for this stock on November 02, 2020, and assigned it a price target of $67. In a note dated October 15, 2020, H.C. Wainwright upgraded an Buy rating on this stock and boosted its target price from $25 to $54.
Replimune Group Inc [REPL] stock has fluctuated between $4.92 and $12.97 over the past year. Currently, Wall Street analysts expect the stock to reach $24.2 within the next 12 months. Replimune Group Inc [NASDAQ: REPL] shares were valued at $14.93 at the most recent close of the market. An investor can expect a potential return of 62.09% based on the average REPL price forecast.
Analyzing the REPL fundamentals
Gross Profit Margin for this corporation currently stands at 0.48% with Operating Profit Margin at -57.29%, Pretax Profit Margin comes in at -52.6%, and Net Profit Margin reading is -52.7%. To continue investigating profitability, this company’s Return on Assets is posted at -0.43, Equity is -0.53 and Total Capital is -0.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 13.04 points at the first support level, and at 11.15 for the second support level. However, for the 1st resistance point, the stock is sitting at 16.91, and for the 2nd resistance point, it is at 18.89.
Ratios To Look Out For
For context, Replimune Group Inc’s Current Ratio is 10.11. Further, the Quick Ratio stands at 10.11, while the Cash Ratio is 2.59.
Transactions by insiders
Recent insider trading involved Xynos Konstantinos, Chief Medical Officer, that happened on Nov 18 ’24 when 7246.0 shares were sold. Chief Commercial Officer, Sarchi Christopher completed a deal on Nov 18 ’24 to sell 5207.0 shares. Meanwhile, Chief Financial Officer Hill Emily Luisa sold 8938.0 shares on Aug 16 ’24.
